Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy.
Journal Article (Journal Article)
Subset analysis of patients with sarcomatoid renal cell carcinoma (sRCC) included in the CheckMate 214 trial of ipilimumab-nivolumab versus sunitinib showed improved outcomes in sRCC with ipilimumab-nivolumab. The use of checkpoint inhibitor-based regimens in sRCC, for which therapeutic options were once limited, is further supported by additional clinical trials.See related article by Tannir et al., p. 78.
Full Text
Duke Authors
Cited Authors
- Hwang, JK; Agarwal, N; Brugarolas, J; Zhang, T
Published Date
- January 1, 2021
Published In
Volume / Issue
- 27 / 1
Start / End Page
- 5 - 7
PubMed ID
- 33106290
Pubmed Central ID
- PMC7785667
Electronic International Standard Serial Number (EISSN)
- 1557-3265
Digital Object Identifier (DOI)
- 10.1158/1078-0432.CCR-20-3506
Language
- eng
Conference Location
- United States